Risankizumab – BiotechReality – Information Intelligence System for Biopharma

AbbVie Announces Phase 3 AFFIRM study successfully met its co-primary and ranked secondary endpoints, demonstrating that SKYRIZI® (risankizumab) delivered via subcutaneous (SC) induction is superior to placebo in inducing clinical remission and endoscopic response in adults with moderately to severely active Crohn’s disease (CD). These results are significant as they establish the efficacy of an SC-only induction pathway, potentially offering a more flexible administration option for patients compared to traditional intravenous (IV) induction. Study Overview and Methodology Study Name: AFFIRM (NCT06063967) Design: Global, Phase 3, randomized, double-blind, placebo-controlled. Population: 289 adult patients with moderately to severely active Crohn’s disease. Patient Profile: 65% of the population was "treatment-refractory" (had failed at least one advanced therapy). 50% had failed two or more advanced therapies. Treatment Arms: Patients were randomized 2:1 to receive either risankizumab (SC) or a placebo. Primary Endpoints: 1. Clinical Remission: Defined by a Crohn’s Disease Activity Index (CDAI) score 50% reduction in SES-CD from baseline. Read More: AbbVie and Genmab Announce Positive Phase 3 Results for Epcoritamab in Relapsed/Refractory DLBCL Key Efficacy Results (Week 12) Risankizumab SC induction showed statistically significant superiority over placebo across all evaluated groups at the 12-week mark. MetricRisankizumab SCPlaceboP-ValueClinical Remission (Overall)55%30%< 0.0001Endoscopic Response (Overall)44%14%< 0.0001Clinical Remission (Bio-Naïve)73.1%27.3%SignificantClinical Remission (Prior Bio-Failure)45.2%30.8%Significant Clinical Significance & Market Impact Innovation in Administration: Most current biologics for Crohn’s disease require an initial intravenous (IV) loading dose in a clinical setting. The AFFIRM study validates a subcutaneous-only induction regimen. This shift could: Increase patient convenience by allowing home-based or simplified administration. Reduce the burden on infusion centers. Provide a competitive edge for AbbVie in the immunology market against other IL-23 and TNF inhibitors. AbbVie Last Modified:

Tag: Risankizumab

AbbVie Announces Phase 3 AFFIRM Study of Risankizumab (SKYRIZI®) for Crohn’s Disease

Areas Covered

Discover More

GSK Secures Japan Orphan Drug Designation for Risvutatug Rezetecan in Small-Cell Lung Cancer

Pfizer’s Talzenna + Xtandi Delivers Proven rPFS Breakthrough in HRR-Mutated mCSPC

Eli Lilly Declares Powerful 2% A1C Reduction and 17% Weight Loss in Landmark Phase 3 Trial Results of Retatrutide

ICOTYDE FDA Approval: J&J’s First-Line Oral Peptide Breakthrough for Plaque Psoriasis Treatment

Atirmociclib Phase 2 Breakthrough: Pfizer Declares Powerful Results for Metastatic Breast Cancer Treatment

EBGLYSS (lebrikizumab-lbkz) Delivers Remarkable Phase 3 Results for Pediatric Atopic Dermatitis Treatment